The presence of CNV of resistance-related genes including EGFR was associated with a poorer response to osimertinib in advanced EGFR-mutated lung adenocarcinoma patients.28 The current study found that anlotinib added to gefitinib led to a 4.9-month extension in PFS compared to gefitinib alone, with a 73% reduction in the risk of progression. This evidence concerns the gene EGFR and lung adenocarcinoma.